Management of pregnant women with increased risk of venous thrombosis
2005; Elsevier BV; Volume: 90; Issue: 3 Linguagem: Inglês
10.1016/j.ijgo.2005.05.003
ISSN1879-3479
AutoresYesim Dargaud, Lucia Rugeri, J. Ninet, Claude Négrier, M.C. Trzeciak,
Tópico(s)Cardiovascular Issues in Pregnancy
ResumoInternational Journal of Gynecology & ObstetricsVolume 90, Issue 3 p. 203-207 Clinical articles Management of pregnant women with increased risk of venous thrombosis Y. Dargaud, Corresponding Author Y. Dargaud [email protected] Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, France Service d'Angiologie - Explorations Vasculaires, Hôpital Edouard Herriot, Lyon, FranceCorresponding author. Laboratoire d'Hémostase pav. E, Hôpital Edouard Herriot, 5, place d' Arsonval, 69003 Lyon, France. Tel.: +33 4 72 11 73 70; fax: +33 4 72 11 73 12.Search for more papers by this authorL. Rugeri, L. Rugeri Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this authorJ. Ninet, J. Ninet Service de Médecine Interne, Hôpital Edouard Herriot, Lyon, France Service d'Angiologie - Explorations Vasculaires, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this authorC. Negrier, C. Negrier Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this authorM.C. Trzeciak, M.C. Trzeciak Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this author Y. Dargaud, Corresponding Author Y. Dargaud [email protected] Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, France Service d'Angiologie - Explorations Vasculaires, Hôpital Edouard Herriot, Lyon, FranceCorresponding author. Laboratoire d'Hémostase pav. E, Hôpital Edouard Herriot, 5, place d' Arsonval, 69003 Lyon, France. Tel.: +33 4 72 11 73 70; fax: +33 4 72 11 73 12.Search for more papers by this authorL. Rugeri, L. Rugeri Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this authorJ. Ninet, J. Ninet Service de Médecine Interne, Hôpital Edouard Herriot, Lyon, France Service d'Angiologie - Explorations Vasculaires, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this authorC. Negrier, C. Negrier Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this authorM.C. Trzeciak, M.C. Trzeciak Laboratoire d'Hémostase et Unité d'Hémostase Clinique, Hôpital Edouard Herriot, Lyon, FranceSearch for more papers by this author First published: 17 June 2005 https://doi.org/10.1016/j.ijgo.2005.05.003Citations: 23Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Objective: To evaluate the usefulness of score based management of pregnancies with high risk of venous thromboembolism (VTE). Method: 116 consecutive pregnancies in 109 women with confirmed thrombophilia and/or history of VTE were studied. Patients were managed in accordance with international recommendations. Recently, a VTE risk prediction score was established. An independent group assessed retrospectively and in a blinded way the usefulness of this score. Results: Of the 116 pregnancies, an antithrombotic prophylaxis by low molecular weight heparin was prescribed in 61 cases (52.6%). All patients with a positive score (n = 57, 49.1%) have been treated with an antenatal thromboprophylaxis. In the population where the score was negative (n = 55 cases), none of the patients received antenatal prophylaxis. But, despite a negative score, four patients were treated by their general practitioner. During the study period, there was only one episode of VTE. Conclusion: Implementing this scoring system has resulted in favorable outcomes and a low risk of recurrent thrombosis in this limited series of women with increased risk of VTE. References [1]Lindqvist P., Dahlback B., Marsal K. Thrombotic risk during pregnancy : a population study. Obstet Gynecol. 94: 1999; 595–599 [2]Ray J.G., Chan W.S. Deep vein thrombosis during pregnancy and the puerperium : a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 54: 1999; 265–271 [3]Bates S.M., Greer I.A., Hirsh J., Ginsberg J.S. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 126: 2004; 627S–644S [4]Empson M., Lassere M., Craig J.C., Scott J.R. Recurrent pregnancy loss with antiphospholipid antibody : a systematic review of therapeutic trials. Obstet Gynecol. 99: 2002; 135–144 [5]Conard J., Horellou M.H., Van Dreden P., Lecompte T., Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S : study of 78 women. Thromb Haemost. 63: 1990; 319–320 [6]Ginsberg J.S., Bates M. Management of venous thromboembolism during pregnancy. J Thromb Haemost. 1: 2003; 1435–1442 [7]Martinelli I., Legnani C., Bucciarelli P., Grandone E., De Stefano V., Mannucci P.M. Risk of pregnancy related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost. 86: 2001; 800–803 [8]Gerhardt A., Scharf R.E., Beckmann M.W., Struve S., Bender H.G., Pillny M., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 342: 2000; 374–380 [9]Samama M.M., Rached R.A., Horellou M.H., Aquilanti S., Mathieux V.G., Plu-Bureau G., et al. Pregnancy associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210A mutation and in heterozygous FII single gene mutation alone. Br J Haematol. 123: 2003; 327–334 [10]Mc Coll M.D., Ramsay J.E., Tait R.C., Walker I.D., Mc Call F., Conkie J.A., et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 78: 1997; 1183–1188 [11]Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 87: 2002; 791–795 [12]Greer I.A. Thrombosis in pregnancy : maternal and fetal issues. Lancet. 353: 1999; 1258–1265 [13]Prandoni P., Lensing A.W., Prins M.H., Bernardi E., Marchiori A., Bagatella P., et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 137: 2002; 955–960 [14]Janssen H.F., Schachner J., Hubbard J., Hartman T. The risk of deep venous thrombosis: a computerized epidemiologic approach. Surgery. 101: 1987; 205–212 [15]Ray J.G., Chan W.S. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 54: 1999; 265–271 Citing Literature Volume90, Issue3September 2005Pages 203-207 ReferencesRelatedInformation
Referência(s)